X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast cancer (10) 10
index medicus (9) 9
oncology (8) 8
humans (6) 6
aged (5) 5
chemotherapy (5) 5
female (5) 5
middle aged (5) 5
trastuzumab (5) 5
cancer (4) 4
care and treatment (4) 4
erbb-2 protein (4) 4
survival (4) 4
therapy (4) 4
adult (3) 3
breast neoplasms - drug therapy (3) 3
cancer therapies (3) 3
chemotherapy, adjuvant (3) 3
clinical trials (3) 3
efficacy (3) 3
patients (3) 3
surgery (3) 3
analysis (2) 2
anastrozole (2) 2
antimetabolites, antineoplastic - adverse effects (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
cancer research (2) 2
capecitabine (2) 2
carcinoma, ductal, breast - drug therapy (2) 2
carcinoma, ductal, breast - surgery (2) 2
cell biology (2) 2
combination (2) 2
deoxycytidine - adverse effects (2) 2
deoxycytidine - analogs & derivatives (2) 2
docetaxel (2) 2
endocrine therapy (2) 2
gemcitabine (2) 2
hematology (2) 2
lapatinib plus capecitabine (2) 2
letrozole (2) 2
medicine (2) 2
medicine & public health (2) 2
metastases (2) 2
metastasis (2) 2
monoclonal-antibody (2) 2
multidisciplinary sciences (2) 2
paclitaxel (2) 2
paralytic ileus (2) 2
postmenopausal women (2) 2
progesterone (2) 2
receptor, erbb-2 - genetics (2) 2
receptor, erbb-2 - metabolism (2) 2
research (2) 2
science (2) 2
settore med/06 - oncologia medica (2) 2
studies (2) 2
tumors (2) 2
usage (2) 2
women (2) 2
1st-line treatment (1) 1
abemaciclib (1) 1
adherence to therapy (1) 1
adherence to therapy adjuvant endocrine therapy breast cancer oral drugs recursive partitioning and amalgamation analysis (1) 1
adjuvant (1) 1
adjuvant endocrine therapy (1) 1
adjuvant therapy (1) 1
adjuvant therapy; clinical practice; early breast cancer; her2; trastuzumab (1) 1
adjuvant trastuzumab (1) 1
adjuvant treatment (1) 1
adjuvants, pharmaceutic - therapeutic use (1) 1
advanced breast cancer, hormonal therapy (1) 1
adverse drug reaction (1) 1
age factors (1) 1
aged, 80 and over (1) 1
agriculture, dairy & animal science (1) 1
algorithms (1) 1
algoritm (1) 1
american-society (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antioxidant (1) 1
antioxidants (1) 1
aromatase (1) 1
aromatase inhibition (1) 1
aromatase inhibitors (1) 1
aromatase inhibitors - administration & dosage (1) 1
atac trial (1) 1
biological effects (1) 1
body weight (1) 1
brain cancer (1) 1
breast (1) 1
breast cancer; hormonal adjuvant therapy; nonadherence to therapy (1) 1
breast neoplasms - diagnosis (1) 1
breast neoplasms - epidemiology (1) 1
breast neoplasms - genetics (1) 1
breast neoplasms - mortality (1) 1
breast neoplasms - pathology (1) 1
breast neoplasms - surgery (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2013, Volume 141, Issue 1, pp. 119 - 123
The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this... 
Metastatic disease | Medicine & Public Health | Endocrine therapy | Oncology | Gonadotropin-releasing hormone analog | Male breast cancer | Letrozole | ONCOLOGY | AROMATASE INHIBITION | ESTROGEN | BUSERELIN | EXPRESSION | Triazoles - administration & dosage | Cyclophosphamide - administration & dosage | Neoplasms, Hormone-Dependent - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Breast Neoplasms, Male - surgery | Estrogens | Humans | Middle Aged | Male | Epirubicin - administration & dosage | Mastectomy, Modified Radical | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Carcinoma, Ductal, Breast - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Chemotherapy, Adjuvant | Methotrexate | Radiotherapy, Adjuvant | Gonadotropin-Releasing Hormone - agonists | Carcinoma, Ductal, Breast - secondary | Fluorouracil | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Goserelin - administration & dosage | Carcinoma, Ductal, Breast - surgery | Estrogen Receptor Modulators - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Papillary - drug therapy | Combined Modality Therapy | Breast Neoplasms, Male - drug therapy | Carcinoma, Papillary - surgery | Breast Neoplasms, Male - radiotherapy | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Ductal, Breast - radiotherapy | Aged | Neoplasms, Hormone-Dependent - drug therapy | Progesterone | Care and treatment | Pituitary hormones | Development and progression | Breast cancer | Metastasis | Gonadotropin | Cancer
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 06/2019, Volume 234, Issue 6, pp. 7708 - 7717
Journal Article
by De Placido, Sabino and Gallo, Ciro and De Laurentiis, Michelino and Bisagni, Giancarlo and Arpino, Grazia and Sarobba, Maria Giuseppa and Riccardi, Ferdinando and Russo, Antonio and Del Mastro, Lucia and Cogoni, Alessio Aligi and Cognetti, Francesco and Gori, Stefania and Foglietta, Jennifer and Frassoldati, Antonio and Amoroso, Domenico and Laudadio, Lucio and Moscetti, Luca and Montemurro, Filippo and Verusio, Claudio and Bernardo, Antonio and Lorusso, Vito and Gravina, Adriano and Moretti, Anna and Moretti, Gabriella and Lauria, Rossella and Lai, Antonella and Mocerino, Carmela and Rizzo, Sergio and Nuzzo, Antonio and Nuzzo, Francesco and Carlini, Paolo and Perrone, Francesco and Accurso, Antonello and Agostara, Biagio and Aieta, Michele and Alabiso, Oscar and Alicicco, Maria Grazia and Amadori, Dino and Amaducci, Laura and Amiconi, Gianna and Antuzzi, Giustino and Ardine, Mara and Ardizzoia, Antonio and Aversa, Caterina and Badalamenti, Giuseppe and Barni, Sandro and Basurto, Carlo and Berardi, Rossana and Bergamasco, Cinzia and Bidoli, Paolo and Bighin, Claudia and Biondi, Edoardo and Boni, Corrado and Borgonovo, Karen and Botta, Mario and Bravi, Stefano and Bruzzi, Paolo and Buono, Giuseppe and Butera, Alfredo and Caldara, Alessia and Candeloro, Giampiero and Cappelletti, Claudia and Cardalesi, Cinzia and Carfora, Elisabetta and Cariello, Anna and Carrozza, Francesco and Cartenì, Giacomo and Caruso, Michele and Casadei, Virginia and Casanova, Claudia and Castori, Luigi and Cavanna, Luigi and Cavazzini, Giovanna and Cazzaniga, Marina and Chilelli, Mario and Chiodini, Paolo and Chiorrini, Silvia and Ciardiello, Fortunato and Ciccarese, Mariangela and Cinieri, Saverio and Clerico, Mario and Coccaro, Mariarosa and Comande, Mario and Corbo, Claudia and Cortino, Giuseppina and Cusenza, Stefania and Daniele, Gennaro and D'arco, Alfonso Maria and D'auria, Giuliana and Dazzi, Claudio and De Angelis, Carmine and de Braud, Filippo and De Feo, Gianfranco and De Matteis, Andrea and De Tursi, Michele and Di Blasio, Anna and di Lucca, Giuseppe and Di Lullo, Liberato and Di Rella, Francesca and Di Renzo, Gianfranco and ... and GIM Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 474 - 485
Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly... 
SYSTEM | THERAPY | EFFICACY | ONCOLOGY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | COMBINATION | AROMATASE INHIBITORS | Breast cancer | Product development | Tamoxifen | Analysis
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, p. e0136731
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 3/2016, Volume 142, Issue 3, pp. 669 - 678
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 34, pp. 56921 - 56931
We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in... 
HER2 positive | Metastatic breast cancer | T-DM1 | Previous pertuzumab | Real-world | EFFICACY | PHASE-II | MONOCLONAL-ANTIBODY | PERTUZUMAB | DOCETAXEL | CHEMOTHERAPY | CELL BIOLOGY | real-world | GROWTH-FACTOR RECEPTOR | THERAPY | metastatic breast cancer | LAPATINIB PLUS CAPECITABINE | previous pertuzumab
Journal Article
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 6/2012, Volume 18, Issue 2, pp. 299 - 302
Journal Article
Journal Article
Journal of cellular physiology, 12/2018
Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with... 
Journal Article